$4.055
-0.409 (-10.09%)Zum Schluss
ALGS-News
ALGS-Events
Aligos Therapeutics Reports Q3 Revenue of $2.83M
Reports Q3 revenue $2.83M, consensus $5.54M. "This past quarter we continued to advance our Phase 2 B-SUPREME study of pevifoscorvir sodium, which remains on track for the topline data readout in late Q3 2027," stated Lawrence Blatt, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. "With enrollment complete and 70 participants having completed 48 weeks of treatment, the study continues to progress toward the anticipated topline data readout. We remain enthusiastic about pevifoscorvir sodium's potential, as well as our ASO ALG-170675, which is currently in a Phase 1 study in China with our partner Amoytop. With these recent developments, we believe we are one step closer to our goal of bringing effective therapies to people living with chronic HBV infection."
Aligos Therapeutics Q2 Revenue $27.78M, Exceeds Expectations
Reports Q2 revenue $27.78M, consensus $13.18M. "Our team has continued to execute on our key strategic priorities to advance our pipeline this year," stated Lawrence Blatt, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. "We strengthened our financial position through non-dilutive capital, including the $25M upfront payment related to the exclusive Greater China license for pevifoscorvir sodium. In addition, our partner Amoytop has advanced our potential best-in-class ASO for chronic HBV infection, bringing the program through IND approval in China, resulting in a $3M milestone payment. Pevifoscorvir sodium continues to make significant progress, highlighted by the completion of enrollment for the Phase 2 B-SUPREME study and the receipt of Breakthrough Designation in China for chronic HBV infection. As we look ahead to topline data from the B-SUPREME study which is expected in late Q3 next year, we remain confident that our differentiated pipeline has the potential to meaningfully reduce the burden of end-stage liver disease and liver cancer, the main goal of chronic HBV infection treatment."
Aligos Therapeutics Completes Enrollment in B-SUPREME Study
Aligos Therapeutics announced that it has completed enrollment of both the HBeAg+ and HBeAg- participants in the Phase 2 B-SUPREME study of pevifoscorvir sodium, under development for the treatment of chronic hepatitis B virus infection. Topline safety and efficacy data are expected to be available in late third quarter of 2027.
Large-Cap Growth Stocks Shine, Crinetics Pharmaceuticals Up 100%
Risk-on sentiment resurfaced following the long holiday weekend as large-cap growth areas of the market handily outperformed SMIDs and value. Comms Services, Tech, and Financials were the best performing sectors on the S&P 500, while the defensively oriented Healthcare, Staples, and Utilities lagged. Computer Hardware had an especially strong day - Arista Networkswas up 8.3%, Western Digitalgained 7.1% and Seagaterallied 5.9%. A softer than expected non-farm payrolls dented expectations of tightening, but that narrative was also defied by the price action in the Treasury market as yields on the short-end of the curve remained elevated while longer-dated maturities remain elevated. Service ISM data also came in softer somewhat, though the indicator remained in expansion - as it has for the past two years.In the evening hours, equity index futures are mixed - S&P e-minis are flat while Nasdaq 100 is off by 0.2%. In commodities, WTI Crude Oil is marginally higher but still below $70 per barrel while precious and base metals are up by about 0.2%.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER -Crinetics Pharmaceuticalsup 100% after being acquired by Vertex Pharmaceuticals, which is down 2.3%Aligos Therapeuticsup 14.9% after receiving a $25M upfront payment for pevifoscorvir sodium license dealFirst Solarup 2.1% after being upgraded to buy at Deutsche BankRentokil Initial plcup 1.9% after being upgraded to Buy at Goldman SachsAbbVieup 0.3% after Q2 pre-announcementLOWER -Riviandown 8.8% after 75M share equity offering.
Aligos Therapeutics Receives $25M Upfront Payment
Aligos Therapeutics announced that it has received the upfront payment of $25M from the exclusive license deal of pevifoscorvir sodium in Greater China with Xiamen Amoytop Biotech. In addition, pevifoscorvir sodium was granted Breakthrough Therapy Designation from the Center for Drug Evaluation of China's National Medical Products Administration. Under the terms of the agreement, Aligos is also eligible to receive up to $420M in clinical, regulatory, and sales milestones along with tiered, high single-digit royalties on net sales in Amoytop's licensed territories. Aligos retains all development and commercialization rights for pevifoscorvir sodium in the United States, Europe, South Korea, Japan, and all other markets.
Ähnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.